Biocardia stock.

SUNNYVALE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...Most recently, on Friday, May 26th, Peter Altman bought 6,200 shares of BioCardia stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $9,920.00. Following the completion of the transaction, the chief executive officer now directly owns 469,239 shares of the company's stock, valued at $750,782.40.The Wall Street analyst predicted. that Biocardia's share price could reach $4.00 by Nov 14, 2024. The average Biocardia stock price prediction forecasts a potential upside of 495.24% from the current BCDA share price of $0.67.SUNNYVALE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the Food and Drug Administration (FDA) approval of its Phase III clinical trial of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.BioCardia, Inc. Stock price Equities BCDA US09060U5074 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials …

Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive ... BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...

2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Nov 14, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%? Nov 29, 2023 · On Tuesday, BioCardia Inc. [NASDAQ:BCDA] saw its stock fall -0.55% to $0.69. On the same session, the stock had its day’s lowest price of $0.60, but rose to a high of $0.6873. Over the last five days, the stock has lost -4.68%. BioCardia Inc. shares have fallen nearly -67.16% since the year began. Nov 16, 2023 · "Subsidiary" shall have the meaning ascribed to such term in Section 3.1(a). "Trading Day" means a day on which the principal Trading Market is open for trading. "Trading Market" means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq ... mediaphotos. BioCardia (NASDAQ:BCDA) signed an agreement to provide its catheter biotherapeutic delivery product candidates for BlueRock Therapeutics' cell therapy products to treat heart failure ...BCDA Stock Shows Promising Performance with Potential 863.86% Increase: Analysts Recommend Buying BioCardia Inc. BCDA stock has shown promising performance on November 7, 2023, according to data sourced from CNN Money. The median target price is $4.00, indicating a potential increase of 863.86% from the last …

BioCardia Inc. (NASDAQ:BCDA) trade information. BioCardia Inc. (BCDA) registered a 8.23% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.23% in intraday trading to $0.67 this Friday, 12/01/23, hitting a weekly high. The stock’s 5-day price performance is -5.22%, and it has moved by 77.43% in ...

At the time of writing, BioCardia Inc. [BCDA] stock is trading at $0.68, down -0.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The BCDA shares have gain 7.94% over the last week, with a monthly amount glided 78.71%, and seem to be holding up well over

Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued.David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq ...Nov 15, 2023 · BioCardia Inc’s (NASDAQ: BCDA) stock has experienced a remarkable surge of 225.70% following the FDA’s recent approval of the Phase 3 CardiAMP Heart Failure II study protocol for their innovative CardiAMP autologous cell therapy for ischemic heart failure. Dec 15, 2022 · The gross proceeds to BioCardia, before deducting fees and other offering expenses, are expected to be approximately $3.6 million. The closing of the sale of the securities is expected to occur on ... When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...

Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Stock split history for BioCardia since 2019. Prices shown are actual historical values and are not adjusted for either splits or dividends.The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics …Looking to buy BCDAW Stock? View today's BCDAW stock price, trade commission-free, and discuss BioCardia Inc. - Warrants (26/07/2022) stock updates with the investor community.BioCardia (BCDA) In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on BioCardia, with a price target of $4.00 . The company’s shares closed last Tuesday ...

2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 08 NovBioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months.

BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector include Apellis Pharmaceuticals APLS, Avid Bioservices CDMO and Biohaven BHVN, also ...Nov 14, 2023 · BioCardia Inc (BCDA) stock is unmoved 0% while the S&P 500 is higher by 1.44% as of 4:00 PM on Monday, Nov 13. BCDA is unmoved $0.00 from the previous closing price of $0.40 on volume of 39,170,298 shares. Over the past year the S&P 500 has gained 13.09% while BCDA has fallen -78.61%. BCDA lost -$0.63 per share the over the last 12 months. BioCardia ®, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation for the CardiAMP ® Cell Therapy System for the treatment of heart failure. It is believed to be the first cardiac …BioCardia currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the overall healthcare sector include Apellis Pharmaceuticals APLS, Avid Bioservices CDMO and Biohaven BHVN, also ...BioCardia ( NASDAQ: BCDA) shares jumped over +105% premarket on Tuesday after the biotech firm received FDA approval for the Phase 3 clinical trial of its CardiAMP autologous cell therapy for the ...Convert BioCardia Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. Select a stock. apple; wise; Select a currency. USD. NASDAQ: BioCardia Inc (BCDAW) = 0.06 USD. Provided by Alpha Vantage. BioCardia Inc stock (BCDAW) in USD. 1 BCDAW = 0.06 USD. 1 month.Insiders trading at BioCardia. Over the last 7 years, insiders at BioCardia have traded over $2,500,000 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer, and Richard M Krasno.On average, BioCardia executives and independent …

Find the latest BioCardia, Inc. (BCDAW) stock quote, history, news and other vital information to help you with your stock trading and investing.

The estimated Net Worth of David Mc Clung is at least $440 Thousand dollars as of 5 November 2018. Mr. Clung owns over 1,600 units of BioCardia stock worth over $5,952 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $434,495 as Chief Financial Officer at BioCardia.

You can buy and sell BioCardia (BCDA) and other stocks, ETFs, and options commission-free on Robinhood with real-time quotes, market data, and relevant news. Other Robinhood Financial fees may apply, check rbnhd.co/fees for details. ... BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular ...Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for ...On Tuesday, BioCardia Inc. [NASDAQ:BCDA] saw its stock fall -0.55% to $0.69. On the same session, the stock had its day’s lowest price of $0.60, but rose to a high of $0.6873. Over the last five days, the stock has lost -4.68%. BioCardia Inc. shares have fallen nearly -67.16% since the year began.BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.Nov 29, 2023 · A high-level overview of BioCardia, Inc. (BCDA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. See the latest BioCardia Inc stock price (BCDA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

The estimated Net Worth of Peter Altman is at least $747 Mille dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $69,056 and over the last 6 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer e Director at BioCardia.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 2d Why Beyond Air Shares Are Trading Lower By Around 37%?Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM.Instagram:https://instagram. low float penny stockspublic advertising companiesphlx semiconductor indexreal estate limited partnerships BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 0% and 614%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?Nov 29, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 18d Why Beyond Air Shares Are Trading Lower By Around 37%? innovation refund reviewstarget skechers Discover historical prices for BCDA stock on Yahoo Finance. View daily, weekly or monthly format back to when BioCardia, Inc. stock was issued. which dental insurance is best SAN CARLOS, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- BioCardia ®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months …BioCardia Inc. analyst ratings, historical stock prices, earnings estimates & actuals. BCDA updated stock price target summary.